Answers are grounded in this paper and cite their sources.
Patients with hematologic malignancies have increased susceptibility to viral infections and suboptimal immunologic responses to current vaccines due to both disease-associated and therapy-related immune dysfunction. These considerations may impact the efficacy of emerging COVID-19 vaccines in this patient population as well and warrant the need to systematically study natural and vaccine-induced virus-specific immunity in these patients.
No takes yet. Share an insight, caveat, or question.
Dhodapkar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: